vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Gaming & Leisure Properties, Inc. (GLPI). Click either name above to swap in a different company.
Gaming & Leisure Properties, Inc. is the larger business by last-quarter revenue ($420.0M vs $281.3M, roughly 1.5× Guardant Health, Inc.). Gaming & Leisure Properties, Inc. runs the higher net margin — 57.0% vs -45.7%, a 102.7% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 6.3%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 5.0%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Gaming and Leisure Properties, Inc. is a real estate investment trust (REIT) specializing in casino properties, based in Wyomissing, Pennsylvania. It was formed in November 2013 as a corporate spin-off from Penn National Gaming. The company owns 62 casino properties, all of which are leased to other companies.
GH vs GLPI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $420.0M |
| Net Profit | $-128.5M | $239.4M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 79.4% |
| Net Margin | -45.7% | 57.0% |
| Revenue YoY | 39.4% | 6.3% |
| Net Profit YoY | -15.8% | 40.5% |
| EPS (diluted) | $-1.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $420.0M | ||
| Q4 25 | $281.3M | $407.0M | ||
| Q3 25 | $265.2M | $397.6M | ||
| Q2 25 | $232.1M | $394.9M | ||
| Q1 25 | $203.5M | $395.2M | ||
| Q4 24 | $201.8M | $389.6M | ||
| Q3 24 | $191.5M | $385.3M | ||
| Q2 24 | $177.2M | $380.6M |
| Q1 26 | — | $239.4M | ||
| Q4 25 | $-128.5M | $275.4M | ||
| Q3 25 | $-92.7M | $241.2M | ||
| Q2 25 | $-99.9M | $151.4M | ||
| Q1 25 | $-95.2M | $165.2M | ||
| Q4 24 | $-111.0M | $223.6M | ||
| Q3 24 | $-107.8M | $184.7M | ||
| Q2 24 | $-102.6M | $208.3M |
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — |
| Q1 26 | — | 79.4% | ||
| Q4 25 | -43.0% | 89.3% | ||
| Q3 25 | -37.3% | 84.8% | ||
| Q2 25 | -45.9% | 61.3% | ||
| Q1 25 | -54.6% | 65.5% | ||
| Q4 24 | -62.4% | 79.1% | ||
| Q3 24 | -61.3% | 70.4% | ||
| Q2 24 | -56.8% | 77.1% |
| Q1 26 | — | 57.0% | ||
| Q4 25 | -45.7% | 67.6% | ||
| Q3 25 | -35.0% | 60.7% | ||
| Q2 25 | -43.0% | 38.4% | ||
| Q1 25 | -46.8% | 41.8% | ||
| Q4 24 | -55.0% | 57.4% | ||
| Q3 24 | -56.3% | 47.9% | ||
| Q2 24 | -57.9% | 54.7% |
| Q1 26 | — | — | ||
| Q4 25 | $-1.01 | $0.96 | ||
| Q3 25 | $-0.74 | $0.85 | ||
| Q2 25 | $-0.80 | $0.54 | ||
| Q1 25 | $-0.77 | $0.60 | ||
| Q4 24 | $-0.90 | $0.79 | ||
| Q3 24 | $-0.88 | $0.67 | ||
| Q2 24 | $-0.84 | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $274.5M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $5.0B |
| Total Assets | $2.0B | $13.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $274.5M | ||
| Q4 25 | $378.2M | — | ||
| Q3 25 | $580.0M | — | ||
| Q2 25 | $629.1M | — | ||
| Q1 25 | $698.6M | — | ||
| Q4 24 | $525.5M | $560.8M | ||
| Q3 24 | $585.0M | $560.8M | ||
| Q2 24 | $933.7M | $560.8M |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | $7.2B | ||
| Q3 25 | $1.1B | $7.2B | ||
| Q2 25 | $1.1B | $6.9B | ||
| Q1 25 | $1.1B | $6.9B | ||
| Q4 24 | $1.1B | $7.7B | ||
| Q3 24 | — | $7.4B | ||
| Q2 24 | — | $6.6B |
| Q1 26 | — | $5.0B | ||
| Q4 25 | $-99.3M | $4.6B | ||
| Q3 25 | $-354.5M | $4.6B | ||
| Q2 25 | $-305.5M | $4.6B | ||
| Q1 25 | $-250.8M | $4.2B | ||
| Q4 24 | $-139.6M | $4.3B | ||
| Q3 24 | $-60.1M | $4.3B | ||
| Q2 24 | $-1.6M | $4.1B |
| Q1 26 | — | $13.8B | ||
| Q4 25 | $2.0B | $12.9B | ||
| Q3 25 | $1.3B | $12.8B | ||
| Q2 25 | $1.3B | $12.5B | ||
| Q1 25 | $1.3B | $12.1B | ||
| Q4 24 | $1.5B | $13.1B | ||
| Q3 24 | $1.5B | $12.7B | ||
| Q2 24 | $1.6B | $11.8B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.56× | ||
| Q3 25 | — | 1.57× | ||
| Q2 25 | — | 1.51× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.81× | ||
| Q3 24 | — | 1.74× | ||
| Q2 24 | — | 1.60× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | — |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-26.4M | $1.1B | ||
| Q3 25 | $-35.4M | $240.3M | ||
| Q2 25 | $-60.3M | $293.4M | ||
| Q1 25 | $-62.7M | $252.5M | ||
| Q4 24 | $-64.5M | $1.1B | ||
| Q3 24 | $-51.1M | $270.4M | ||
| Q2 24 | $-94.0M | $252.1M |
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | $183.0M | ||
| Q2 25 | $-65.9M | $272.3M | ||
| Q1 25 | $-67.1M | $239.6M | ||
| Q4 24 | $-83.4M | $1.1B | ||
| Q3 24 | $-55.3M | $261.5M | ||
| Q2 24 | $-99.1M | $245.0M |
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | 46.0% | ||
| Q2 25 | -28.4% | 69.0% | ||
| Q1 25 | -33.0% | 60.6% | ||
| Q4 24 | -41.3% | 275.3% | ||
| Q3 24 | -28.9% | 67.9% | ||
| Q2 24 | -55.9% | 64.4% |
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | — | ||
| Q3 25 | 3.9% | 14.4% | ||
| Q2 25 | 2.4% | 5.3% | ||
| Q1 25 | 2.2% | 3.3% | ||
| Q4 24 | 9.4% | 0.0% | ||
| Q3 24 | 2.2% | 2.3% | ||
| Q2 24 | 2.9% | 1.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.10× | ||
| Q3 25 | — | 1.00× | ||
| Q2 25 | — | 1.94× | ||
| Q1 25 | — | 1.53× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.46× | ||
| Q2 24 | — | 1.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
GLPI
Segment breakdown not available.
